Phathom Pharmaceuticals published a real-world retrospective analysis comparing outcomes in adults with erosive esophagitis treated with vonoprazan or PPIs. The

Phathom Pharmaceuticals published a real-world retrospective analysis comparing outcomes in adults with erosive esophagitis treated with vonoprazan or PPIs. The study adds to evidence that could inform future treatment decisions and research.